News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation

Study Status:

Open for enrollment

Contact Information:

(956) 362-2378

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To determine the effect of once-daily, oral administration of 80 or 100 mg MGL-3196 versus matching placebo on NASH

Information: 

Principal Investigator
Fernando Membreno, MD
Co-PI
John Rodriguez
Sponsor
Madrigal Pharmaceuticals, Inc.
Type of Trial
Interventional
© 2024 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram